Changes in Hong Kong stocks | Yingpai Pharmaceutical-B (07630) fell more than 13% in the afternoon, down nearly 70% since the beginning of July, the total market value is less than HK$3.5 billion

The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) fell by more than 13% in the afternoon. As of press release, it was down 12.47% to HK$11.58, with a turnover of HK$5.277,400.

According to news, on July 30, Yingpai Pharmaceutical announced that it signed an exclusive licensing agreement with Pharmmanovia to grant it exclusive production, development and commercialization rights for senaparib (senaparib) to maintain monotherapy for advanced epithelial high-grade ovarian cancer, fallopian tube cancer, and primary peritoneal cancer in Europe, the Middle East, North Africa, Australia and New Zealand. Yingpai Pharmaceuticals can collect up to 423.5 million euros in total.

It is worth noting that the market previously generally predicted that because Yingpai Pharmaceutical meets the Hong Kong Stock Connect market capitalization requirements, it will be successfully included in the Hong Kong Stock Connect in September 2026. According to reports, with the current September Hong Kong Stock Connect adjustment, the closing market value on June 30 is the assessment benchmark. However, after the assessment was implemented, the stock quickly plummeted and plummeted 45% on July 2. Since then, the stock price has continued to plummet. As of August 3, the market capitalization was less than HK$3.5 billion.